Physician profile
Peter Nguyen
NPI 1164717104
$36,163.50
in general payments reported to CMS, 2019-2025
33 companies · $1,060 in 2025
The $1,060 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,302 · 2020: $21K · 2021: $1,805 · 2022: $2,440 · 2023: $2,604 · 2024: $3,952 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,285 · Travel and Lodging: $3,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,285.11 |
| Travel and Lodging | $3,331.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $21,084.49 | 2019-2020 | |
| Edwards Lifesciences Corporation | $4,781.77 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Evoque |
| Abbott Laboratories | $3,000.63 | 2019-2024 | Mitraclip, Amplatzer Amulet |
| Medtronic, INC. | $2,261.43 | 2021-2025 | Corevalve Evolut R, Apollotm |
| Boston Scientific Corporation | $1,131.63 | 2019-2025 | Avvigo Guidance System |
| Merz North America, INC. | $1,035.24 | 2021 | |
| Abiomed | $507.95 | 2019-2024 | Impella |
| Philips North America LLC | $450.00 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $265.38 | 2019-2022 | |
| Pfizer INC. | $202.53 | 2019-2023 | |
| W. L. Gore & Associates, INC. | $150.87 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $140.70 | 2022-2023 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $137.52 | 2022-2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $118.07 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $114.53 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $99.51 | 2022-2023 | Repatha |
| Terumo Medical Corporation | $94.12 | 2019 | |
| Cook Medical LLC | $77.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $66.70 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.34 | 2022-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $58.26 | 2019 | |
| Janssen Biotech, INC. | $50.12 | 2023 | Stelara |
| Cardiovascular Systems INC. | $45.94 | 2019 | |
| Becton, Dickinson and Company | $43.92 | 2025 | Rotarexs 6 F X 135 Cm |
| Alnylam Pharmaceuticals INC. | $33.47 | 2024 | Onpattro |
| Cardiva Medical, INC. | $27.14 | 2022 | |
| Impulse Dynamics (USA) INC. | $22.95 | 2023 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $21.40 | 2022 | |
| Shockwave Medical, INC | $16.20 | 2022 | |
| Atricure, INC. | $15.64 | 2022 | |
| Ge Healthcare | $14.32 | 2025 | |
| Penumbra, INC. | $13.68 | 2022 | |
| Siemens Medical Solutions USA, INC. | $13.57 | 2023 | Naeotom Alpha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.